APA

Kampylafka E., Simon D., d'Oliveira I., Linz C., Lerchen V., Englbrecht M., Rech J., Kleyer A., Sticherling M., Schett G. & Hueber A. J. (20200826). Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. : Arthritis research & therapy.

Chicago

Kampylafka Eleni, Simon David, d'Oliveira Isabelle, Linz Christina, Lerchen Veronika, Englbrecht Matthias, Rech Juergen, Kleyer Arnd, Sticherling Michael, Schett Georg and Hueber Axel J. 20200826. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. : Arthritis research & therapy.

Harvard

Kampylafka E., Simon D., d'Oliveira I., Linz C., Lerchen V., Englbrecht M., Rech J., Kleyer A., Sticherling M., Schett G. and Hueber A. J. (20200826). Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. : Arthritis research & therapy.

MLA

Kampylafka Eleni, Simon David, d'Oliveira Isabelle, Linz Christina, Lerchen Veronika, Englbrecht Matthias, Rech Juergen, Kleyer Arnd, Sticherling Michael, Schett Georg and Hueber Axel J. Disease interception with interleukin-17 inhibition in high-risk psoriasis patients with subclinical joint inflammation-data from the prospective IVEPSA study. : Arthritis research & therapy. 20200826.